Pharmacological therapy used in the elimination of Helicobacter pylori infection: A Review

被引:26
作者
dos Santos, Ariolana A. [1 ]
Carvalho, Adriana A. [1 ]
机构
[1] Univ Fed Sergipe, Dept Pharm, BR-4940000 Lagarto, Sergipe, Brazil
关键词
Clarithromycin resistant; Helicobacter pylori; Peptic ulcers; Triple therapy; Treatment; RANDOMIZED CONTROLLED-TRIAL; STANDARD TRIPLE THERAPIES; SEQUENTIAL THERAPY; QUADRUPLE THERAPY; ERADICATION RATE; OPEN-LABEL; H; PYLORI; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; CHINESE PATIENTS;
D O I
10.3748/wjg.v21.i1.139
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
The optimal therapy for Helicobacter pylori (H. pylori) infection should combine a high cure rate and a short treatment duration with a favorable side-effect profile and should maintain a low cost. Several strategies have been proposed to increase the H. pylori eradication rate, including the extension of the treatment duration to 14 d, the use of a four-drug regimen (quadruple, sequential, and concomitant treatments), and the use of novel antibiotics, such as levofloxacin. However, triple therapy remains the most widely accepted first-line treatment regimen in Brazil and the United States and throughout Europe. Because this therapy is limited by resistance to clarithromycin, other therapeutic regimens have been investigated worldwide. This review describes the current literature involving studies directly comparing these different therapies and their efficacies.
引用
收藏
页码:139 / 154
页数:16
相关论文
共 54 条
[1]
Agah Shahram, 2009, Saudi J Gastroenterol, V15, P225, DOI 10.4103/1319-3767.56091
[2]
[Anonymous], 2013, Prescrire Int, V22, P89
[3]
Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study [J].
Assem, M. ;
El Azab, G. ;
Rasheed, M. Abdel ;
Abdelfatah, M. ;
Shastery, M. .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2010, 21 (04) :310-314
[4]
Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial [J].
Bago, Josip ;
Majstorovic, Karolina ;
Belosic-Halle, Zeljka ;
Kucisec, Nastja ;
Bakula, Vinko ;
Tomic, Monika ;
Bago, Petra ;
Troskot, Rosana .
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2010, 9
[5]
Bang So Young, 2007, Korean J Gastroenterol, V50, P356
[6]
Bytzer P, 2011, DAN MED BULL, V58
[7]
Comparison of the Efficacy of the Two Tetracycline-Containing Sequential Therapy Regimens for the Eradication of Helicobacter Pylori: 5 days Versus 14 days Amoxicillin [J].
Cetinkaya, Zueleyha A. ;
Sezikli, Mesut ;
Guzelbulut, Fatih ;
Cosgun, Sueleyman ;
Duzgun, Serkan ;
Kurdas, Oya Oe .
HELICOBACTER, 2010, 15 (02) :143-147
[8]
Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study [J].
Chen, L. -W. ;
Chien, R. -N. ;
Chang, J. -J. ;
Fang, K. -M. ;
Chang, L. -C. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (11) :1530-1534
[9]
Levofloxacin-Amoxicillin/Clavulanate-Rabeprazole versus a Standard Seven-Day Triple Therapy for Eradication of Helicobacter pylori Infection [J].
Chen, Ming-Cheh ;
Lei, Wei-Yi ;
Lin, Jen-Shung ;
Yi, Chih-Hsun ;
Wu, Deng-Chyang ;
Hu, Chi-Tan .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[10]
American college of gastroenterology guideline on the management of Helicobacter pylori infection [J].
Chey, William D. ;
Wong, Benjamin C. Y. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (08) :1808-1825